
    low recruitment of participants for the study
  
['hiv-1 infection', 'treatment resistant disorders', 'viremia']
['protease inhibitor', 'isentress® (raltegravir)']

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  HIV-1 infection

          -  On combined antiretroviral regimen for at least 18 months

          -  Participant with a stable antiretroviral regimen for at least 6 months, including 2
             Reverse-transcriptase inhibitor (INTI) + 1 Boosted Protease Inhibitor IP/r ,

          -  participant with at least 2 consecutive viral load between 50 and 500
             copies/milliliter over the last 9 months (with at least 2 months between the two
             measurements) quantified with the same commercial kit.

          -  50 <or= VL < 500 copies/milliliter at screening visit quantified with the same
             commercial kit than previous one.

          -  Participant naïve to raltegravir (RAL)

          -  failure of amplification or successful realization of genotypic resistance test
             without evidence for resistance mutations against current treatment (3TC/FTC accepted
             with M184V mutation)

          -  creatinin < 3 Upper Limit normal (ULN)

          -  Aspartate Amino Transférase (ASAT), Alanine Amino Transférase (ALAT) < 5 Upper Limit
             normal (ULN)

          -  hemoglobin > 8 g/dL

          -  platelets > 50 000/mm3

          -  In women, lack of current pregnancy verified by Beta Human Chorionic Gonadotropin
             (βHCG) at week -4 visit and use of a mechanical contraceptive method

          -  Informed consent

          -  Participants with an active health insurance coverage (article L1121-11 du Code de la
             Santé Publique)

        Exclusion Criteria:

          -  HIV-2 infection,

          -  severe medical condition in the last month (inclusion is possible for a stable
             condition at screening)

          -  breastfeeding women, current pregnancy or planned pregnancy within 12 months.

          -  participant currently receiving Prezista® (darunavir)/ Norvir® (ritonavir) (600/100
             mg) two times a day (BID) (of note, participants receiving Prezista® (darunavir)/
             Norvir® (ritonavir) one time a day (QD) can be included)

          -  Hypersensitivity Prezista® (darunavir)/ Norvir® (ritonavir) or to any of the
             excipients of the study treatment

          -  participant under judicial protection (judicial protection due to temporarily and
             slightly diminished mental or physical faculties), or under legal guardianship

          -  planned absence that could prevent the patient from participating in the trial (travel
             abroad, moving, pending work transfer ...)
      